{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:08:56Z","timestamp":1791472136628,"version":"4.3.4"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Research Foundation\u2014Flanders, Belgium","award":["1SF2924N"],"award-info":[{"award-number":["1SF2924N"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Importance and objective<\/jats:title>\n                  <jats:p>It remains unclear if patients on escalated intravenous (IV) infliximab can switch to standard subcutaneous (SC) infliximab CT-P13 of 120\u2009mg bi-weekly (Q2W) injections without losing therapeutic response. This study investigates the dose\u2013exposure\u2013response relationship during the IV-to-SC switching of infliximab in Crohn\u2019s disease (CD) and ulcerative colitis (UC).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design, setting, participants, and intervention(s)<\/jats:title>\n                  <jats:p>Data were collected from healthy volunteers and patients with CD and UC in different Phase I studies. In patients, PK, fecal calprotectin (FC), and endoscopic remission (ER) in CD or endoscopic improvement (EI) in UC were measured during switching from 5\u2009mg\/kg IV infliximab to Q2W SC infliximab injections of 120\/180\/240\u2009mg. We performed population pharmacokinetics\u2013pharmacodynamics modeling and simulation (n\u2009=\u20091000 virtual patients) to evaluate FC time courses and probabilities of ER\/EI post-switch.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main outcome(s) and measure(s)<\/jats:title>\n                  <jats:p>Fecal calprotectin levels decreased when overall infliximab exposure (not just infliximab trough concentrations) increased. Lower FC at week (w)14 was associated with increased probabilities of EI in UC, but not ER in CD. Simulations showed that the standard infliximab IV-to-SC switch at w6 further decreases FC and results in a higher probability of EI at w22\/30 (54% if no switch vs 63% if switch). Virtual patients on escalated Q6W\/Q8W IV maintenance regimens up to 10\u2009mg\/kg can switch to 120\u2009mg Q2W SC infliximab without FC increases. In addition, we translated our model into a clinical software tool to guide the IV-to-SC switch of infliximab.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions and relevance<\/jats:title>\n                  <jats:p>Patients on Q6W and Q8W IV regimens may switch to standard SC infliximab without an increase in FC.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjaf151","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T16:16:53Z","timestamp":1756397813000},"source":"Crossref","is-referenced-by-count":3,"title":["Optimizing the switch from escalated intravenous to subcutaneous infliximab: a population pharmacokinetics\u2013pharmacodynamics study"],"prefix":"10.1093","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6415-2044","authenticated-orcid":false,"given":"Zhigang","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical and Pharmacological Sciences, KU Leuven , Leuven,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1492-0716","authenticated-orcid":false,"given":"Marc","family":"Ferrante","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, UZ Leuven , Leuven,","place":["Belgium"]},{"name":"Department of Chronic Diseases and Metabolism, KU Leuven , Leuven,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9942-3019","authenticated-orcid":false,"given":"S\u00e9verine","family":"Vermeire","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, UZ Leuven , Leuven,","place":["Belgium"]},{"name":"Department of Chronic Diseases and Metabolism, KU Leuven , Leuven,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0785-2930","authenticated-orcid":false,"given":"Erwin","family":"Dreesen","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Pharmacological Sciences, KU Leuven , Leuven,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"key":"2025092419313468100_jjaf151-B1","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","article-title":"Crohn\u2019s disease","volume":"389","author":"Torres","year":"2017","journal-title":"Lancet"},{"key":"2025092419313468100_jjaf151-B2","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"2025092419313468100_jjaf151-B3","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/00054725-199811000-00014","article-title":"Infliximab approved for use in Crohn\u2019s disease: a report on the FDA GI Advisory Committee conference","volume":"4","author":"Kornbluth","year":"1998","journal-title":"Inflamm Bowel Dis"},{"key":"2025092419313468100_jjaf151-B4","doi-asserted-by":"crossref","first-page":"1868078","DOI":"10.1080\/19420862.2020.1868078","article-title":"Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters","volume":"13","author":"Kim","year":"2021","journal-title":"MAbs"},{"key":"2025092419313468100_jjaf151-B5","doi-asserted-by":"crossref","first-page":"4366","DOI":"10.1007\/s12325-021-01834-3","article-title":"Infliximab biosimilar CT-P13 observational studies for rheumatoid arthritis, inflammatory bowel diseases, and ankylosing spondylitis: pooled analysis of long-term safety and effectiveness","volume":"38","author":"Cheon","year":"2021","journal-title":"Adv Ther"},{"key":"2025092419313468100_jjaf151-B6","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1053\/j.gastro.2021.02.068","article-title":"Randomized controlled trial: subcutaneous vs intravenous infliximab CT-P13 maintenance in inflammatory bowel disease","volume":"160","author":"Schreiber","year":"2021","journal-title":"Gastroenterology"},{"key":"2025092419313468100_jjaf151-B7","author":"European Medicines Agency (EMA)"},{"key":"2025092419313468100_jjaf151-B8","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1007\/s12325-021-01990-6","article-title":"Perspectives on subcutaneous infliximab for rheumatic diseases and inflammatory bowel disease: before, during, and after the COVID-19 era","volume":"39","author":"Schreiber","year":"2022","journal-title":"Adv Ther"},{"key":"2025092419313468100_jjaf151-B9","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40259-018-0295-0","article-title":"Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities","volume":"32","author":"Bittner","year":"2018","journal-title":"BioDrugs"},{"key":"2025092419313468100_jjaf151-B10","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/j.cgh.2022.08.011","article-title":"Effectiveness of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel diseases: the REMSWITCH study","volume":"21","author":"Buisson","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025092419313468100_jjaf151-B11","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1016\/j.cgh.2023.01.004","article-title":"Therapeutic drug monitoring can guide the intravenous-to-subcutaneous switch of infliximab and vedolizumab: a simulation study","volume":"21","author":"Wang","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025092419313468100_jjaf151-B12","doi-asserted-by":"crossref","first-page":"2040622319838443","DOI":"10.1177\/2040622319838443","article-title":"Infliximab in inflammatory bowel disease","volume":"10","author":"Papamichael","year":"2019","journal-title":"Ther Adv Chronic Dis"},{"key":"2025092419313468100_jjaf151-B13","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1093\/ecco-jcc\/jjac009","article-title":"Introduction of subcutaneous infliximab CT-P13 and vedolizumab in clinical practice: a multi-stakeholder position statement highlighting the need for post-marketing studies","volume":"16","author":"Fierens","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2025092419313468100_jjaf151-B14","first-page":"A161","article-title":"P0387 subcutaneous administration of a novel formulation of CT-P13 (infliximab biosimilar) is safe and achieves projected therapeutic drug levels: a phase I study in healthy subjects","volume":"5","author":"Westhovens","year":"2017","journal-title":"United European Gastroenterol J"},{"key":"2025092419313468100_jjaf151-B15","author":"European Medicines Agency","year":"2019"},{"key":"2025092419313468100_jjaf151-B16","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1111\/apt.16609","article-title":"Population pharmacokinetics of subcutaneous infliximab CT-P13 in Crohn\u2019s disease and ulcerative colitis","volume":"54","author":"Hanzel","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"2025092419313468100_jjaf151-B17","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/psp4.12689","article-title":"Easy and reliable maximum a posteriori Bayesian estimation of pharmacokinetic parameters with the open-source R package mapbayr","volume":"10","author":"Le Louedec","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2025092419313468100_jjaf151-B18","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/FTD.0000000000001204","article-title":"Best practice for therapeutic drug monitoring of infliximab: position statement from the international association of therapeutic drug monitoring and clinical toxicology","volume":"46","author":"Alsoud","year":"2024","journal-title":"Ther Drug Monit"},{"key":"2025092419313468100_jjaf151-B19","doi-asserted-by":"crossref","first-page":"115421","DOI":"10.1016\/j.addr.2024.115421","article-title":"Model-informed precision dosing: state of the art and future perspectives","volume":"215","author":"Minichmayr","year":"2024","journal-title":"Adv Drug Deliv Rev"},{"key":"2025092419313468100_jjaf151-B20","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1189\/jlb.70.1.130","article-title":"Mechanism of extracellular release of human neutrophil calprotectin complex","volume":"70","author":"Voganatsi","year":"2001","journal-title":"J Leukoc Biol"},{"key":"2025092419313468100_jjaf151-B21","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1080\/00365529950172835","article-title":"Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease","volume":"34","author":"R\u00f8seth","year":"1999","journal-title":"Scand J Gastroenterol"},{"key":"2025092419313468100_jjaf151-B22","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1053\/j.gastro.2015.07.003","article-title":"Biomarkers of inflammation in inflammatory bowel disease","volume":"149","author":"Sands","year":"2015","journal-title":"Gastroenterology"},{"key":"2025092419313468100_jjaf151-B23","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"2025092419313468100_jjaf151-B24","doi-asserted-by":"crossref","first-page":"i1866","DOI":"10.1093\/ecco-jcc\/jjae190.1182","article-title":"P1008 subcutaneous infliximab in IBD patients previously treated with an optimized intravenous infliximab dosing schedule: preliminary results on expectations and satisfaction of switching from intravenous to subcutaneous infliximab","volume":"19","author":"Moens","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2025092419313468100_jjaf151-B25","doi-asserted-by":"crossref","first-page":"e081787","DOI":"10.1136\/bmjopen-2023-081787","article-title":"Switching from Dose-Intensified Intravenous to SubCutaneoUS infliximab in Inflammatory Bowel Disease (DISCUS-IBD): protocol for a multicentre randomised controlled trial","volume":"14","author":"Little","year":"2024","journal-title":"BMJ Open"}],"container-title":["Journal of Crohn\u2019s and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjaf151\/64149638\/jjaf151.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/8\/jjaf151\/64149638\/jjaf151.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/8\/jjaf151\/64149638\/jjaf151.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T23:31:42Z","timestamp":1758756702000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjaf151\/8242763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,9,7]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf151","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,8]]},"article-number":"jjaf151"}}